本帖最后由 老马 于 2012-1-13 21:20 编辑 1 X6 c# i- v- r( j
- n) |, O" c' ^" F% L+ c/ R爱必妥和阿瓦斯丁的比较6 x) y3 M% O- w; r3 I/ a
' X* [& j7 a5 ]9 r2 u: Q
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/- n' b8 L0 N8 u. R O+ x
D. G) Y& h1 t$ L
5 E" t/ w& o0 n1 w0 {' O
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
, \4 j V6 ~$ j. a0 @& b" v==================================================6 [8 E0 n0 f. L
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 S, J' E$ D3 f/ I/ d0 DPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.% }0 W8 c+ \" b4 x2 L" f) x$ T+ g. Q
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
1 r: C5 P& R+ ~; C5 C
|